Rothschild Investment Corp IL Increases Stock Position in Illumina, Inc. (NASDAQ:ILMN)


Share on StockTwits

Rothschild Investment Corp IL lifted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 12.2% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 691 shares of the life sciences company’s stock after buying an additional 75 shares during the period. Rothschild Investment Corp IL’s holdings in Illumina were worth $265,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Private Ocean LLC increased its holdings in shares of Illumina by 238.1% in the 4th quarter. Private Ocean LLC now owns 71 shares of the life sciences company’s stock worth $26,000 after buying an additional 50 shares during the last quarter. Carroll Financial Associates Inc. bought a new stake in shares of Illumina in the 4th quarter worth about $31,000. Evolution Wealth Advisors LLC bought a new stake in shares of Illumina in the 4th quarter worth about $31,000. CVA Family Office LLC bought a new stake in shares of Illumina in the 1st quarter worth about $31,000. Finally, Clearview Wealth Advisors LLC bought a new stake in shares of Illumina in the 4th quarter worth about $32,000. Hedge funds and other institutional investors own 89.97% of the company’s stock.

A number of equities analysts have commented on ILMN shares. OTR Global upgraded shares of Illumina to a “positive” rating in a research note on Tuesday, December 22nd. SVB Leerink upped their target price on shares of Illumina from $360.00 to $470.00 and gave the stock an “outperform” rating in a research note on Friday, February 12th. Canaccord Genuity upped their target price on shares of Illumina from $445.00 to $460.00 and gave the stock a “buy” rating in a research note on Tuesday, April 13th. BTIG Research upped their target price on shares of Illumina from $410.00 to $570.00 and gave the stock a “buy” rating in a research note on Tuesday, February 16th. Finally, Piper Sandler upped their target price on shares of Illumina from $415.00 to $510.00 and gave the stock an “overweight” rating in a research note on Friday, February 12th. Four analysts have rated the stock with a sell rating, nine have issued a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $374.10.

In other Illumina news, Director Jay T. Flatley sold 4,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 6th. The shares were sold at an average price of $423.44, for a total transaction of $1,693,760.00. Also, SVP Susan H. Tousi sold 800 shares of the company’s stock in a transaction that occurred on Friday, March 5th. The shares were sold at an average price of $402.24, for a total transaction of $321,792.00. Following the transaction, the senior vice president now owns 44,943 shares in the company, valued at approximately $18,077,872.32. The disclosure for this sale can be found here. Insiders have sold a total of 9,114 shares of company stock worth $3,830,491 in the last 90 days. 0.38% of the stock is currently owned by company insiders.

NASDAQ:ILMN opened at $398.39 on Wednesday. Illumina, Inc. has a 52 week low of $260.42 and a 52 week high of $555.77. The firm has a 50 day moving average of $403.80 and a 200 day moving average of $375.78. The company has a quick ratio of 3.51, a current ratio of 3.88 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $58.13 billion, a price-to-earnings ratio of 92.43, a PEG ratio of 9.83 and a beta of 1.14.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, February 11th. The life sciences company reported $1.22 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.11 by $0.11. Illumina had a net margin of 19.70% and a return on equity of 15.93%. The business had revenue of $953.00 million for the quarter, compared to analyst estimates of $949.65 million. As a group, analysts expect that Illumina, Inc. will post 4.39 EPS for the current year.

Illumina Profile

Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

Featured Story: Why is insider trading harmful?

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.